Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.

Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.

Show other versions (1)

Bone abnormalities affect all individuals with Down syndrome (DS) and are linked to abnormal expression of DYRK1A, a gene found in three copies in people with DS and Ts65Dn DS model mice. Previous work in Ts65Dn male mice demonstrated that both genetic normalization of Dyrk1a and treatment with ~9 m...

Full description

Bibliographic Details
Main Authors: Raza Jamal, Jonathan LaCombe, Roshni Patel, Matthew Blackwell, Jared R Thomas, Kourtney Sloan, Joseph M Wallace, Randall J Roper
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0264254

Internet

https://doi.org/10.1371/journal.pone.0264254

Similar Items